SFX by Ex Libris Inc.

Title:	Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease
Source:	Science [0036-8075] Dunah, A W yr:2002

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Davies, S W W. "Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation." Cell 90.3 (1997): 537-548.
description	2.	Bae, Byoung-Il I. "p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease." Neuron 47.1 (2005): 29-41.
description	3.	Ross, C A A. "Intranuclear neuronal inclusions: A common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?" Neuron 19.6 (1997): 1147-1150.
description	4.	Harjes, P. "The hunt for huntingtin function: interaction partners tell many different stories." Trends in biochemical sciences 28.8 (2003): 425-433.
description	5.	Zuccato, C. "Role of brain-derived neurotrophic factor in Huntingtons disease." Progress in Neurobiology 81.5-6 (2007): 294-330.
description	6.	DiFiglia, M. "Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain." Science 277.5334 (1997): 1990-1993.
description	7.	Mangiarini, L. "Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice." Cell 87.3 (1996): 493-506.
description	8.	Cattaneo, E. "Normal huntingtin function: An alternative approach to Huntington's disease." Nature reviews. Neuroscience 6.12 (2005): 919-930.
description	9.	Ross, Christopher A A. "Opinion: What is the role of protein aggregation in neurodegeneration?" Nature reviews. Molecular cell biology 6.11 (2005): 891-8.
description	10.	GERBER, H P P. "TRANSCRIPTIONAL ACTIVATION MODULATED BY HOMOPOLYMERIC GLUTAMINE AND PROLINE STRETCHES." Science 263.5148 (1994): 808-811.
description	11.	Scherzinger, E. "Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo." Cell 90.3 (1997): 549-558.
description	12.	La Spada, Albert R R. "The power of the dark side: Huntington's disease protein and p53 form a deadly alliance." Neuron 47.1 (2005): 1-3.
description	13.	Schilling, A H H. "Widespread expression of Huntington's disease gene (IT15) protein product." Neuron 14.5 (1995): 1065-74.
description	14.	Ross, CA A. "What is the role of protein aggregation in neurodegeneration?" Nature reviews. Molecular cell biology 6.11 (2005): 891-898.
description	15.	Imarisio, Benjamin R C. "Huntington's disease: from pathology and genetics to potential therapies." The Biochemical journal 412.2 (2008): 191-209.
description	16.	Ross, Christopher A A. "Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders." Neuron 35.5 (2002): 819-22.
description	17.	Goldberg, A L L. "The cellular chamber of doom." Scientific American 284.1: 68-73.
description	18.	Hay, B A A. "Expression of baculovirus P35 prevents cell death in Drosophila." Development 120.8 (1994): 2121-9.
description	19.	McCampbell, A. "Histone deacetylase inhibitors reduce polyglutamine toxicity." Proceedings of the National Academy of Sciences of the United States of America 98.26 (2002): 15179-84.
description	20.	Feng, Z. "p53 tumor suppressor protein regulates the levels of huntingtin gene expression." Oncogene 25.1: 1-7.